AG真人官方

On 28 July 2025, Argan, Inc. (NYSE: AGX) filed an Item 8.01 Form 8-K announcing that its wholly owned subsidiary, Atlantic Projects Company, has signed an engineering, procurement and construction (EPC) contract with SSE Thermal for the Platin Power Station in County Meath, Ireland. The plant will employ three Siemens Energy SGT-800 turbines operating in open-cycle mode and is designed to deliver approximately 170 MW of peaking capacity to the Irish grid during demand spikes. Target completion is in 2028.

The filing states that the entire contract value will be added to Argan鈥檚 consolidated project backlog for the period ending 31 July 2025, but the dollar amount was not disclosed. No additional financial guidance, funding details or regulatory contingencies were provided. The disclosure does not amend any prior financial statements.

While the contract enhances multi-year revenue visibility, investors lack information on margin potential, payment schedule or risk-sharing terms, making it difficult to gauge precise earnings impact.

Argan, Inc. (AGX) 鈥� Form 4 Insider Transaction Summary

Director Peter W. Getsinger reported three transactions involving the company鈥檚 common stock:

• Sale: On 26 Jun 2025, he sold 3,456 shares in the open market at $212.01 per share, generating roughly $732.7 thousand in proceeds.
• Gift to Donor-Advised Fund: On 30 Jun 2025, he transferred 1,000 shares at no consideration to a donor-advised fund managed by Martha鈥檚 Vineyard Investment Advisors.
• Family Gift: On the same date, he gifted 999 shares (333 shares each) to his three children.

Following these transactions, Getsinger鈥檚 direct beneficial ownership declined from 18,351 to 12,896 shares, a 29.7 % reduction. No derivative securities were reported.

The filing does not indicate that the sale was executed under a Rule 10b5-1 trading plan. Investors often view sizeable insider sales鈥攑articularly absent a preset plan鈥攁s a potential negative sentiment signal, although philanthropic gifts may be neutral with respect to corporate outlook.

Argan, Inc. (AGX) Form 4 filing: Director William F. Leimkuhler disclosed two open-market sales of the company鈥檚 common stock.

• On 27-Jun-2025, he sold 4,051 shares at an average price of $221.25.
• On 30-Jun-2025, he sold 7,604 shares at an average price of $222.03.

The combined sale of 11,655 shares generated proceeds of roughly $2.6 million (based on the reported average prices). After the transactions, Leimkuhler鈥檚 direct ownership declined from 58,240 to 50,636 shares, a reduction of about 13%. No derivative securities activity was reported.

The filing signals insider selling by a non-executive director; investors often view such activity as a potential indicator of reduced near-term confidence, though it may also reflect personal portfolio decisions rather than a view on fundamentals.

Argan, Inc. (AGX) 鈥� Form 144 insider notice filed 06/26/2025

Director Peter W. Getsinger has filed a Notice of Proposed Sale of Securities pursuant to Rule 144. The filing covers 3,465 common shares intended for sale through Morgan Stanley Smith Barney LLC on or after 06/26/2025. The shares were acquired on 06/23/2025 via the cash exercise of stock options under a registered plan. The aggregate market value of the planned sale is listed at $734,630.59, while Argan reports 13,640,813 shares outstanding. The transaction will take place on the NYSE, the company鈥檚 primary exchange.

The director has been an active seller in recent months. The filing discloses six previous sales between 04/14/2025 and 04/16/2025 totaling 7,292 shares for combined gross proceeds of approximately $1.07 million. Rule 144 requires aggregation of sales over a three-month period; therefore, the forthcoming 3,465-share sale would bring the director鈥檚 disclosed three-month total to 10,757 shares.

The signer affirms that he is not aware of any undisclosed material adverse information about Argan. No additional company operational or financial data are provided in this filing.

Form 4 Filing Details: Peter W. Getsinger, Director of Argan (AGX), exercised stock options and acquired shares on June 23, 2025. Key transaction details:

• Exercised 10,000 stock options at $71.75 per share using net settlement method
• Options were originally awarded on January 5, 2017, with expiration date of January 5, 2027
• Acquired 6,465 common shares through this transaction
• Post-transaction holdings: 18,351 direct common shares and 34,500 remaining stock options

This insider transaction represents a standard option exercise by a board member, with the net settlement method resulting in fewer shares being issued than the original option amount due to covering the exercise cost.

Form 4 overview: On 06/17/2025, Argan, Inc. (AGX) director Peter W. Getsinger reported the award of 530 Time-Based Restricted Stock Units (TRSUs) with an exercise price of $0. These derivative securities can convert into an equal number of common shares once vested.

Vesting schedule: The TRSUs will vest completely on 04/17/2026, provided the director remains in service. No non-derivative share transactions, sales, or additional purchases were disclosed.

Post-transaction holdings: Following the grant, Getsinger now beneficially owns 3,947 derivative securities tied to AGX common stock, all held directly. The filing does not indicate any change to his direct common-share ownership.

Investor relevance: The grant appears to be routine board compensation. Given the small size鈥�530 units鈥攖he award is immaterial relative to Argan鈥檚 public float and is unlikely to influence share supply, earnings per share, or short-term insider-sentiment indicators.

Key takeaway: On 17 June 2025, Argan, Inc. (AGX) filed a Form 4 showing that director Cynthia Flanders received 530 time-based restricted stock units (RSUs) under the company鈥檚 equity incentive plan.

The RSUs were reported under Transaction Code 鈥淎鈥� (grant/acquisition) at a price of $0, meaning no cash changed hands. According to the footnote, the entire block will vest on 17 June 2026, at which point each RSU converts into one share of common stock.

After this award, Ms. Flanders now beneficially owns 3,947 RSUs in total, all held directly. The filing contains no sales, exercises, or disposals, and there is no indication that the award was made under a Rule 10b5-1 trading plan.

Because the grant involves a small number of shares relative to Argan鈥檚 total shares outstanding and is routine director compensation, it carries minimal immediate financial or dilution impact. Investors may, however, view the award as part of standard governance practice that aligns director incentives with shareholder interests.

Argan director William F. Leimkuhler reported receiving 530 Time-Based Restricted Stock Units (TRSUs) on June 17, 2025. The TRSUs, which have a conversion price of $0, represent the right to receive an equivalent number of Argan common stock shares.

Key details of the transaction:

• The TRSUs will fully vest on April 17, 2026
• Following the transaction, Leimkuhler beneficially owns 3,947 derivative securities directly
• The grant appears to be part of the company's director compensation program

This Form 4 filing, submitted on June 28, 2025, complies with SEC regulations requiring insiders to report changes in their beneficial ownership of company securities within two business days of the transaction.

Karen Sweeney, Director at Argan (AGX), reported multiple transactions involving Time-Based Restricted Stock Units (TRSUs):

• On June 20, 2025, 1,300 TRSUs vested and were converted to common stock (adjusted for dividends, resulting in 1,315 shares) following a one-year vesting schedule from the June 2024 award
• On June 17, 2025, received a new grant of 530 TRSUs, scheduled to vest fully on April 17, 2026

Following these transactions, Sweeney directly owns 1,705 shares of common stock and 530 unvested TRSUs. All transactions were executed at $0 exercise price, consistent with typical TRSU arrangements. These equity awards are part of the company's director compensation program.